Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats

Xiaofang Zhang, Xiaodong Zhang, Bojun Yuan, Lijun Ren, Tianbao Zhang and Guocai Lu
Additional contact information
Xiaofang Zhang: Center for Evaluation of Drug Safety, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China
Xiaodong Zhang: Center for Evaluation of Drug Safety, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China
Bojun Yuan: Center for Evaluation of Drug Safety, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China
Lijun Ren: Center for Evaluation of Drug Safety, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China
Tianbao Zhang: Center for Evaluation of Drug Safety, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China
Guocai Lu: Center for Evaluation of Drug Safety, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China

IJERPH, 2016, vol. 13, issue 12, 1-22

Abstract: Histone deacetylase inhibitors (HDACIs), such as vorinostat and panobinostat, have been shown to have active effects on many hematologic malignancies, including multiple myeloma and cutaneous T-cell lymphoma. Hydroxamate-based (Hb) HDACIs have very good toxicity profiles and are currently being tested in phases I and II clinical trials with promising results in selected neoplasms, such as bladder carcinoma. One of the Hb-HDACIs, HZ1006, has been demonstrated to be a promising drug for clinical use. The aim of our study was to determine the possible target of toxicity and to identify a non-toxic dose of HZ1006 for clinical use. In our studies, the repeated dosage toxicity of HZ1006 in Beagle dogs and Sprague Dawley (SD) rats was identified. Dogs and rats received HZ1006 orally (0–80 and 0–120 mg/kg/day, respectively) on a continuous daily dosing agenda for 28 days following a 14-day dosage-free period. HZ1006’s NOAEL (No Observed Adverse Effect Level) by daily oral administration for dogs and rats was 5 mg/kg and 60 mg/kg, respectively, and the minimum toxic dose was 20 and 120 mg/kg, respectively. All the side effects indicated that the digestive tract, the male reproductive tract, the respiratory tract and the hematological systems might be HZ1006 toxic targets in humans. HZ1006 could be a good candidate or a safe succedaneum to other existing HDACIs for the treatment of some solid tumor and hematologic malignancies.

Keywords: Hb-HDACIs; HZ1006; safety assessment; NOAEL (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2016
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/13/12/1190/pdf (application/pdf)
https://www.mdpi.com/1660-4601/13/12/1190/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:13:y:2016:i:12:p:1190-:d:84135

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().